Statute Details
- Title: Medicines (Cessation of Application of Act to Cosmetic Products) Order 2013
- Act Code: MA1975-S38-2013
- Type: Subsidiary Legislation (SL)
- Authorising Act: Medicines Act (Cap. 176), specifically section 77
- Enacting Formula: Made by the Minister for Health in exercise of powers under section 77 of the Medicines Act
- Citation: Medicines (Cessation of Application of Act to Cosmetic Products) Order 2013
- Commencement: Deemed to have come into operation on 3 October 2011
- Key Provisions: Sections 1–3 (citation/commencement; definition of “cosmetic product”; cessation of application of the Medicines Act to cosmetic products)
- Definition Anchor: “Cosmetic product” is defined by reference to the First Schedule to the Health Products Act (Cap. 122D)
- Status (as provided): Current version as at 27 March 2026
What Is This Legislation About?
The Medicines (Cessation of Application of Act to Cosmetic Products) Order 2013 is a short but legally significant instrument. In essence, it provides that the Medicines Act (Cap. 176) stops applying to cosmetic products from a specified date. The Order is therefore best understood as a regulatory boundary-setting measure: it clarifies that certain products—cosmetics—should not be regulated under the Medicines Act regime.
Although the Order is made in 2013, it is deemed to have commenced on 3 October 2011. This backdating matters for compliance and enforcement questions, because it indicates that the legal change took effect earlier than the date the Order was formally made. Practitioners advising companies must therefore treat 3 October 2011 as the operative date for the cessation of application.
The Order also demonstrates how Singapore’s health-product regulatory framework is organised across different statutes. It defines “cosmetic product” by reference to the First Schedule to the Health Products Act, signalling that cosmetics are intended to fall within the Health Products Act framework rather than the Medicines Act framework.
What Are the Key Provisions?
Section 1 (Citation and commencement) provides the formal title of the Order and, crucially, the commencement rule. The Order “shall be deemed to have come into operation on 3rd October 2011.” In practical terms, this means that even though the Order was made later (the “Made” date is shown as 24 January 2013), the legal effect—cessation of the Medicines Act’s application to cosmetics—was intended to take effect from 3 October 2011.
For lawyers, this is the first provision to check when dealing with historical conduct, product registrations, licensing, enforcement actions, or transitional compliance. If a company’s product was treated as a “medicine” under the Medicines Act after 3 October 2011, the Order may be relevant to arguments about whether the Medicines Act should have applied at all. Conversely, if enforcement occurred after that date, the Order supports the position that cosmetics should not be regulated under the Medicines Act.
Section 2 (Definition) defines “cosmetic product” by reference to another statute: “a cosmetic product referred to in the First Schedule to the Health Products Act (Cap. 122D).” This drafting technique is common in regulatory law. It avoids duplicating definitions and ensures that the meaning of “cosmetic product” stays aligned with the Health Products Act’s scheduled categories.
From a practitioner’s perspective, this cross-reference is critical. The legal classification of a product as a “cosmetic product” depends on the First Schedule under the Health Products Act. Therefore, counsel should not rely solely on marketing descriptions or internal product labels. Instead, they should verify whether the product falls within the scheduled definition or category. If the product is not a “cosmetic product” under that schedule, the cessation provision may not apply, and the Medicines Act could still be relevant.
Section 3 (Cessation of application of Act) is the operative clause. It states that “the provisions of the Act shall cease to apply to any cosmetic product as from 3rd October 2011.” The “Act” referred to is the Medicines Act (Cap. 176), as indicated by the title and the enacting formula.
This clause has a direct regulatory consequence: after 3 October 2011, cosmetics are no longer subject to the Medicines Act’s requirements. While the Order itself does not spell out what replaces the Medicines Act regime, the definitional link to the Health Products Act strongly indicates that cosmetics are intended to be regulated under the Health Products Act instead. Practitioners should therefore treat the Order as a switch-over mechanism between regulatory regimes.
How Is This Legislation Structured?
The Order is structured in a straightforward three-part format:
(1) Section 1: Citation and commencement. This sets the legal identity of the instrument and the effective date (deemed commencement on 3 October 2011).
(2) Section 2: Definition. This defines “cosmetic product” by reference to the First Schedule to the Health Products Act (Cap. 122D).
(3) Section 3: Cessation of application. This provides the substantive legal effect: the Medicines Act provisions cease to apply to cosmetic products from 3 October 2011.
Notably, the Order contains no detailed transitional provisions, enforcement mechanisms, or procedural steps. Its function is to change the legal applicability of the Medicines Act to a defined class of products. The operational compliance requirements for cosmetics would therefore be found in the Health Products Act and its subsidiary instruments, rather than in this Order.
Who Does This Legislation Apply To?
The Order applies to cosmetic products—as defined by reference to the First Schedule to the Health Products Act—and, by consequence, to the persons who deal with such products in Singapore (for example, manufacturers, importers, distributors, and retailers), insofar as their regulatory obligations would otherwise have been governed by the Medicines Act.
However, the Order’s text is product-focused rather than person-focused. It does not directly impose duties on businesses; instead, it determines whether the Medicines Act regime applies to cosmetics at all. Practitioners should therefore advise clients by mapping product classification to the correct regulatory statute: if a product is a “cosmetic product” under the Health Products Act schedule, then the Medicines Act’s provisions should cease to apply from 3 October 2011.
Where there is uncertainty about classification, the cross-reference in Section 2 becomes the key. If a product is misclassified as a cosmetic when it is not within the First Schedule, the cessation provision may not protect the business from Medicines Act requirements. Conversely, if a product is properly classified as a cosmetic, the Medicines Act should not be the governing framework after the commencement date.
Why Is This Legislation Important?
Despite its brevity, the Order is important because it affects the regulatory perimeter of Singapore’s health-product law. In practice, classification determines which statutory controls apply—such as licensing, approval pathways, compliance obligations, and enforcement exposure. By ceasing the application of the Medicines Act to cosmetic products, the Order reduces the risk of over-regulation under the medicines framework and supports a more coherent regulatory approach under the Health Products Act.
The backdated commencement date (deemed operation on 3 October 2011) is also legally significant. It can influence how lawyers assess past compliance. For example, if a company’s compliance programme relied on the Medicines Act for cosmetics after that date, the Order may be relevant to whether the company was required to comply with those Medicines Act provisions. Similarly, in disputes or investigations, the Order can be used to argue that the Medicines Act should not have been applied to cosmetic products from the effective date.
Finally, the Order’s definitional method—linking “cosmetic product” to the Health Products Act’s First Schedule—highlights the need for practitioners to conduct statutory cross-checking. Regulatory advice should be grounded in the current scheduled categories under the Health Products Act, not merely in general industry understanding of what constitutes a cosmetic. This approach reduces classification risk and improves defensibility in regulatory engagements.
Related Legislation
- Medicines Act (Cap. 176)
- Health Products Act (Cap. 122D) (including the First Schedule referenced in the definition)
Source Documents
This article provides an overview of the Medicines (Cessation of Application of Act to Cosmetic Products) Order 2013 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.